전이성 대장암 환자에서 cetuximab 주입 관련반응의 발생 시점과 관련 요인: 위험 기반 관찰 전략을 위한 후향적 코호트 연구.
Purpose: This research aimed to investigate the incidence, severity, timing, and associated factors of cetuximab-induced infusion-related reactions (IRRs) in metastatic colorectal cancer and to inform post-infusion observation strategy. Methods: This retrospective cohort study analyzed medical recor...
| Published in: | Asian Oncology Nursing Vol. 26; no. 2; pp. 95 - 107 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | research tables/charts Journal Article |
| Published: |
Korean Oncology Nursing Society
Jun2026
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=195279741&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 195279741 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 22872434 EU55 jtl: Asian Oncology Nursing issn: 22872434 maglogo: N pubinfo: dt: Jun2026 vid: 26 iid: 2 pid: 72191 pub: Korean Oncology Nursing Society place: , <Blank> artinfo: ui: 195279741 195279741 195279741 10.5388/aon.2026.26.2.95 195279741 ppf: 95 ppct: 12 formats: fmt: @attributes: type: P tig: atl: 전이성 대장암 환자에서 cetuximab 주입 관련반응의 발생 시점과 관련 요인: 위험 기반 관찰 전략을 위한 후향적 코호트 연구. aug: au: 옥오남 김경숙 이세영 홍선영 임준성 남민선 이진희 권인각 affil: 성균관대학교 임상간호대학원 간호임상교수 sug: subj: Antibodies, Monoclonal Adverse Effects Infusions, Intravenous Adverse Effects Drug Hypersensitivity Risk Factors Neoplasm Metastasis Colorectal Neoplasms Drug Therapy Drug Hypersensitivity Epidemiology Risk Assessment Adverse Drug Event Human Retrospective Design Record Review Prospective Studies South Korea Cancer Patients Tertiary Health Care Chi Square Test Fisher's Exact Test Logistic Regression Descriptive Statistics Time Odds Ratio Confidence Intervals Male Female Adult Middle Age Aged Comorbidity Funding Source Adult: 19-44 years Middle Aged: 45-64 years Aged: 65+ years Male Female ab: Purpose: This research aimed to investigate the incidence, severity, timing, and associated factors of cetuximab-induced infusion-related reactions (IRRs) in metastatic colorectal cancer and to inform post-infusion observation strategy. Methods: This retrospective cohort study analyzed medical records of 821 patients treated with cetuximab at a tertiary hospital between 2006 and 2019. IRRs were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. χ² tests, Fisher's exact tests, and logistic regression were used. Results: IRRs occurred in 99 of 821 patients (12.1%), totaling 107 events; 87.9% were grade 1-2 and 12.1% were grade 3-4 (no grade 5 events were observed). Most initial IRRs occurred during the test dose (44.4%) or first full dose (45.5%), and only 10.1% occurred from cycle 2 onward. Median time to onset was 15.5 minutes for the test dose and 60 minutes for the first full dose, and 12 of 13 grade≥3 reactions (92.3%) and all 7 grade 4 reactions occurred within 30 minutes. All 17 IRRs from cycle 2 onward occurred during infusion, with none during the 1-hour post-infusion monitoring. Combined antihistamine--corticosteroid premedication significantly reduced IRR risk versus antihistamine alone (OR=0.60, 95% CI=0.38--0.93, p=.020). Conclusion: Cetuximab-induced IRRs predominantly occur during the first cycle, suggesting the potential for risk-adapted, cycle-differentiated monitoring. These findings provide evidence-based data to support oncology nurses in risk assessment and resource allocation in outpatient chemotherapy, pending multicenter validation. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: Korean refInfo: holdings: @attributes: islocal: N |
|---|